Dendrimers toward Translational Nanotherapeutics: Concise Key Step Analysis.


Journal

Bioconjugate chemistry
ISSN: 1520-4812
Titre abrégé: Bioconjug Chem
Pays: United States
ID NLM: 9010319

Informations de publication

Date de publication:
16 09 2020
Historique:
pubmed: 14 8 2020
medline: 22 6 2021
entrez: 14 8 2020
Statut: ppublish

Résumé

The goal of nanomedicine is to address specific clinical problems optimally, to fight human diseases, and to find clinical relevance to change clinical practice. Nanomedicine is poised to revolutionize medicine via the development of more precise diagnostic and therapeutic tools. The field of nanomedicine encompasses numerous features and therapeutic disciplines. A plethora of nanomolecular structures have been engineered and developed for therapeutic applications based on their multitasking abilities and the wide functionalization of their core scaffolds and surface groups. Within nanoparticles used for nanomedicine, dendrimers as well polymers have demonstrated strong potential as nanocarriers, therapeutic agents, and imaging contrast agents. In this review, we present and discuss the different criteria and parameters to be addressed to prepare and develop druggable nanoparticles in general and dendrimers in particular. We also describe the major requirements, included in the preclinical and clinical roadmap, for NPs/dendrimers for the preclinical stage to commercialization. Ultimately, we raise the clinical translation of new nanomedicine issues.

Identifiants

pubmed: 32786368
doi: 10.1021/acs.bioconjchem.0c00395
doi:

Substances chimiques

Contrast Media 0
Dendrimers 0
Drug Carriers 0
Pharmaceutical Preparations 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2060-2071

Auteurs

Serge Mignani (S)

Université Paris Descartes, PRES Sorbonne Paris Cité, CNRS UMR 860, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique, 45, rue des Saints Peres, 75006 Paris, France.
CQM - Centro de Quı́mica da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal.
Glycovax Pharma, 424 Guy Street, Suite 202, Montreal, Quebec Canada H3J 1S6.

Xiangyang Shi (X)

CQM - Centro de Quı́mica da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal.
State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, PR China.

João Rodrigues (J)

CQM - Centro de Quı́mica da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal.
School of Materials Science and Engineering/Center for Nano Energy Materials, Northwestern Polytechnical University, Xi'an 710072, PR China.

René Roy (R)

Glycovax Pharma, 424 Guy Street, Suite 202, Montreal, Quebec Canada H3J 1S6.

Ángeles Muñoz-Fernández (Á)

Sección Inmunologı́a, Laboratorio InmunoBiologı́a Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Spanish HIV HGM BioBank, Madrid, Spain, Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.

Valentin Ceña (V)

CIBERNED, ISCII, Madrid; Unidad Asociada Neurodeath, Universidad de Castilla-La Mancha, Avda. Almansa, 14, 02006 Albacete, Spain.

Jean-Pierre Majoral (JP)

Laboratoire de Chimie de Coordination du CNRS, 205 route de Narbonne, 31077, Toulouse, Cedex 4, France.
Université Toulouse, 118 route de Narbonne, 31077 Toulouse, Cedex 4, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH